Impact of Tumor Vascularity on Responsiveness to Antiangiogenesis in a Prostate Cancer Stem Cell-Derived Tumor Model

Drugs that target the tumor vasculature and inhibit angiogenesis are widely used for cancer treatment. Individual tumors show large differences in vascularity, but it is uncertain how these differences affect responsiveness to antiangiogenesis. We investigated this question using two closely related prostate cancer models that differ markedly in tumor vascularity: PC3, which has very low vascularity, and the PC3-derived cancer stem-like cell holoclone PC3/2G7, which forms tumors with high microvessel density, high tumor blood flow, and low hypoxia compared with parental PC3 tumors. Three angiogenesis inhibitors (axitinib, sorafenib, and DC101) all induced significantly greater decreases in tumor blood flow and microvessel density in PC3/2G7 tumors compared with PC3 tumors, as well as significantly greater decreases in tumor cell proliferation and cell viability and a greater increase in apoptosis. The increased sensitivity of PC3/2G7 tumors to antiangiogenesis indicates they are less tolerant of low vascularity and suggests they become addicted to their oxygen- and nutrient-rich environment. PC3/2G7 tumors showed strong upregulation of the proangiogenic factors chemokine ligand 2 (CCL2) and VEGFA compared with PC3 tumors, which may contribute to their increased vascularity, and they have significantly lower endothelial cell pericyte coverage, which may contribute to their greater sensitivity to antiangiogenesis. Interestingly, high levels of VEGF receptor-2 were expressed on PC3 but not PC3/2G7 tumor cells, which may contribute to the growth static response of PC3 tumors to VEGF-targeted antiangiogenesis. Finally, prolonged antiangiogenic treatment led to resumption of PC3/2G7 tumor growth and neovascularization, indicating these cancer stem-like cell-derived tumors can adapt and escape from antiangiogenesis. Mol Cancer Ther; 12(5); 787–98. ©2013 AACR.

[1]  R. Bjerkvig,et al.  Tumor vasculature: the Achilles' heel of cancer? , 2013, Expert opinion on therapeutic targets.

[2]  D. Hicklin,et al.  Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies , 2004, Cancer Research.

[3]  E. Crivellato,et al.  The role of pericytes in angiogenesis. , 2011, The International journal of developmental biology.

[4]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[5]  N. Agnantis,et al.  Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer. , 2004, In vivo.

[6]  E. Raymond,et al.  Antiangiogenic treatments and mechanisms of action in renal cell carcinoma , 2012, Investigational New Drugs.

[7]  D. McDonald,et al.  Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. , 2010, Cancer research.

[8]  D. Waxman,et al.  Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib , 2008, Molecular Cancer Therapeutics.

[9]  J. Rich,et al.  Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Jayson,et al.  Intra-tumoural microvessel density in human solid tumours , 2002, British Journal of Cancer.

[11]  J. Llovet,et al.  Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.

[12]  C. Dinney,et al.  Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  Rakesh K. Jain,et al.  Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.

[14]  F. Shojaei,et al.  Anti-angiogenesis therapy in cancer: current challenges and future perspectives. , 2012, Cancer letters.

[15]  D. Waxman,et al.  Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and Axitinib , 2009, Clinical Cancer Research.

[16]  P. Stattin,et al.  Vascular density is a predictor of cancer‐specific survival in prostatic carcinoma , 1997, The Prostate.

[17]  Dickon Hayne,et al.  Randomized, placebo‐controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks , 2005, BJU international.

[18]  R. Epstein.  VEGF signaling inhibitors: More pro-apoptotic than anti-angiogenic , 2007, Cancer and Metastasis Reviews.

[19]  Qiulian Wu,et al.  Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.

[20]  D. Waxman,et al.  Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment , 2007, Molecular Cancer Therapeutics.

[21]  Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system. , 2012, Critical reviews in oncogenesis.

[22]  P. Hahnfeldt,et al.  Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. , 2002, Journal of the National Cancer Institute.

[23]  M. Blagosklonny,et al.  Antiangiogenic therapy and tumor progression. , 2004, Cancer cell.

[24]  P. O'Connor,et al.  Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 , 2008, Clinical Cancer Research.

[25]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[26]  David J. Waxman,et al.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment , 2008, Molecular Cancer Therapeutics.

[27]  D. Pode,et al.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.

[28]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[29]  M. Sharma,et al.  Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis , 2005, Histopathology.

[30]  H. Augustin,et al.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.

[31]  K. Pienta,et al.  CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. , 2010, Cytokine & growth factor reviews.

[32]  M. Reed,et al.  Anti‐angiogenic Therapy: Concept to Clinic , 2012, Microcirculation.

[33]  Limor Chen,et al.  Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. , 2006, Cancer research.

[34]  D. Hinton,et al.  Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. , 2001, Blood.

[35]  L. Ricci-Vitiani,et al.  Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells , 2011, Nature.

[36]  Yihai Cao.  Tumor angiogenesis and molecular targets for therapy. , 2009, Frontiers in bioscience.

[37]  Jorge Yao,et al.  1 a , 25-dihydroxyvitamin D 3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis , 2006 .

[38]  R. Kerbel,et al.  Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. , 2009, Cancer research.

[39]  B. Fenton,et al.  Disparate effects of endostatin on tumor vascular perfusion and hypoxia in two murine mammary carcinomas. , 2003, International journal of radiation oncology, biology, physics.

[40]  I. Fidler,et al.  Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. , 2001, Neoplasia.

[41]  F. Kabbinavar,et al.  Angiogenesis and angiogenic inhibitors in renal cell carcinoma , 2008, Current urology reports.

[42]  B. Ang,et al.  Cancer stem cell: target for anti‐cancer therapy , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  D. Waxman,et al.  PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis , 2010, Molecular Cancer.

[44]  F. Gage,et al.  Cell fusion-independent differentiation of neural stem cells to the endothelial lineage , 2004, Nature.

[45]  C. Dinney,et al.  Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  Rong Wang,et al.  Glioblastoma stem-like cells give rise to tumour endothelium , 2010, Nature.

[47]  D. Schadendorf,et al.  Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: One step forward for overcoming anti‐angiogenic drug resistance? , 2011, Molecular oncology.

[48]  A. Sciarra,et al.  New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects. , 2008, Reviews on recent clinical trials.

[49]  G. Semenza,et al.  Regulation of angiogenesis by hypoxia-inducible factor 1. , 2006, Critical reviews in oncology/hematology.